synendos
synendos.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder
Professor Allan Young Chair of Academic Psychiatry, Imperial College, London Collaboration underway with Prof. Allan Young and King's College, LondonFirst time a Selective Endocannabinoid Reuptake Inhibitor (SERI) molecule is dosed in a patient population
Read more
Report
September 2025
Dr. Andrea Chicca, CEO, shares the highly promising results from Synendos Phase 1 Trials
Read more
Report
September 2025
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials
Read more
Report
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health
The studies established the lead asset to be well tolerated in healthy volunteers at all doses with a good safety profileSYT-510 demonstrated penetration in the central nervous system and a pharmacodynamic effect on the brain BASEL, Switzerland, Sept. 24,
Read more
Report
Pro access
Upgrade to see all 15 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Basel
Switzerland
Registered seat
Financials
Total raised
$22.4M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2020 | $22.4M | Details |